Ridaforolimus is primarily used in oncology research and development, particularly for its antiproliferative properties. It functions as an mTOR (mammalian target of rapamycin) inhibitor, which plays a key role in regulating cell growth, proliferation, and survival. By inhibiting mTOR, ridaforolimus disrupts signaling pathways that cancer cells rely on for growth, making it a candidate for treating various solid tumors and sarcomas. It has been investigated in clinical trials for advanced cancers, including metastatic soft tissue and bone sarcomas, where it demonstrated the ability to prolong progression-free survival. Its application extends to combination therapies, where it is studied alongside chemotherapy or other targeted agents to enhance antitumor efficacy. Additionally, ridaforolimus has been explored for use in preventing tumor recurrence and in managing cancers resistant to conventional treatments. Due to its immunosuppressive and anti-angiogenic effects, it also holds interest in other pathological conditions involving abnormal cell growth and vascularization.